CERo Therapeutics (CERO) Competitors

$0.02 0.00 (0.00%)

As of 05/22/2026 03:06 PM Eastern

CERO vs. ENSC, VCNX, ALBT, CASI, and SBFM

Should you buy CERo Therapeutics stock or one of its competitors? MarketBeat compares CERo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CERo Therapeutics include Ensysce Biosciences (ENSC), Vaccinex (VCNX), Avalon GloboCare (ALBT), CASI Pharmaceuticals (CASI), and Sunshine Biopharma (SBFM). These companies are all part of the "pharmaceutical products" industry.

How does CERo Therapeutics compare to Ensysce Biosciences?

Ensysce Biosciences (NASDAQ:ENSC) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CERo Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 146,241.46%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CERo Therapeutics is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

CERo Therapeutics has lower revenue, but higher earnings than Ensysce Biosciences. Ensysce Biosciences is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.92	-$10.18M	-$3.35	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A

In the previous week, Ensysce Biosciences had 5 more articles in the media than CERo Therapeutics. MarketBeat recorded 6 mentions for Ensysce Biosciences and 1 mentions for CERo Therapeutics. Ensysce Biosciences' average media sentiment score of 0.71 beat CERo Therapeutics' score of 0.00 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ensysce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CERo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CERo Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. CERo Therapeutics' return on equity of 0.00% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
CERo Therapeutics	N/A	N/A	-209.40%

Ensysce Biosciences has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

Summary

CERo Therapeutics beats Ensysce Biosciences on 8 of the 14 factors compared between the two stocks.

How does CERo Therapeutics compare to Vaccinex?

CERo Therapeutics (NASDAQ:CERO) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by insiders. Comparatively, 51.5% of Vaccinex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, CERo Therapeutics had 1 more articles in the media than Vaccinex. MarketBeat recorded 1 mentions for CERo Therapeutics and 0 mentions for Vaccinex. CERo Therapeutics' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
CERo Therapeutics	Neutral
Vaccinex	Neutral

CERo Therapeutics has higher earnings, but lower revenue than Vaccinex. Vaccinex is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A
Vaccinex	$388K	6.70	-$20.25M	-$48.27	N/A

CERo Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

CERo Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 146,241.46%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe CERo Therapeutics is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Vaccinex	N/A	N/A	-383.58%

Summary

CERo Therapeutics beats Vaccinex on 6 of the 11 factors compared between the two stocks.

How does CERo Therapeutics compare to Avalon GloboCare?

CERo Therapeutics (NASDAQ:CERO) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

CERo Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 146,241.46%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe CERo Therapeutics is more favorable than Avalon GloboCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, CERo Therapeutics had 1 more articles in the media than Avalon GloboCare. MarketBeat recorded 1 mentions for CERo Therapeutics and 0 mentions for Avalon GloboCare. CERo Therapeutics' average media sentiment score of 0.00 equaled Avalon GloboCare'saverage media sentiment score.

Company	Overall Sentiment
CERo Therapeutics	Neutral
Avalon GloboCare	Neutral

CERo Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by company insiders. Comparatively, 24.2% of Avalon GloboCare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Avalon GloboCare	N/A	N/A	-74.36%

CERo Therapeutics has higher earnings, but lower revenue than Avalon GloboCare. Avalon GloboCare is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A
Avalon GloboCare	$1.26M	3.68	-$18.26M	-$3.51	N/A

Summary

CERo Therapeutics beats Avalon GloboCare on 7 of the 11 factors compared between the two stocks.

How does CERo Therapeutics compare to CASI Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

CASI Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, CERo Therapeutics had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for CERo Therapeutics and 0 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
CERo Therapeutics	Neutral

CERo Therapeutics has lower revenue, but higher earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A

CASI Pharmaceuticals presently has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. CERo Therapeutics has a consensus target price of $30.00, indicating a potential upside of 146,241.46%. Given CERo Therapeutics' higher possible upside, analysts clearly believe CERo Therapeutics is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

CERo Therapeutics has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
CERo Therapeutics	N/A	N/A	-209.40%

Summary

CASI Pharmaceuticals beats CERo Therapeutics on 7 of the 13 factors compared between the two stocks.

How does CERo Therapeutics compare to Sunshine Biopharma?

CERo Therapeutics (NASDAQ:CERO) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

CERo Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

In the previous week, CERo Therapeutics had 1 more articles in the media than Sunshine Biopharma. MarketBeat recorded 1 mentions for CERo Therapeutics and 0 mentions for Sunshine Biopharma. CERo Therapeutics' average media sentiment score of 0.00 equaled Sunshine Biopharma'saverage media sentiment score.

Company	Overall Sentiment
CERo Therapeutics	Neutral
Sunshine Biopharma	Neutral

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by company insiders. Comparatively, 0.0% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sunshine Biopharma has higher revenue and earnings than CERo Therapeutics. Sunshine Biopharma is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$71.01	N/A
Sunshine Biopharma	$36.31M	0.07	-$5.97M	-$1.29	N/A

CERo Therapeutics has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. CERo Therapeutics' return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

CERo Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 146,241.46%. Sunshine Biopharma has a consensus price target of $7.00, suggesting a potential upside of 1,354.39%. Given CERo Therapeutics' higher probable upside, equities research analysts plainly believe CERo Therapeutics is more favorable than Sunshine Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Sunshine Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Sunshine Biopharma beats CERo Therapeutics on 8 of the 14 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CERO vs. The Competition

Export

Metric	CERo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$754K	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	0.00	17.79	21.22	25.66
Price / Sales	N/A	336.21	562.28	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	0.00	5.86	10.31	7.14
Net Income	-$8.30M	$74.99M	$3.57B	$335.98M
7 Day Performance	N/A	3.11%	6.43%	4.15%
1 Month Performance	N/A	-3.05%	3.57%	2.54%
1 Year Performance	N/A	34.38%	34.07%	35.06%

CERo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CERO CERo Therapeutics	1.123 of 5 stars	$0.02 flat	$30.00 +146,241.5%	-99.8%	$754K	N/A	N/A	8
ENSC Ensysce Biosciences	1.2681 of 5 stars	$0.30 -5.4%	N/A	-85.5%	$2.94M	$5.07M	N/A	10	News Coverage Analyst Revision Gap Down
VCNX Vaccinex	N/A	$1.10 flat	N/A	+47.0%	$2.86M	$388K	N/A	40
ALBT Avalon GloboCare	0.3753 of 5 stars	$0.29 -9.3%	N/A	-89.8%	$2.67M	$1.26M	N/A	5	Gap Up
CASI CASI Pharmaceuticals	1.2094 of 5 stars	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CERO) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CERo Therapeutics (CERO) Competitors

CERO vs. ENSC, VCNX, ALBT, CASI, and SBFM

How does CERo Therapeutics compare to Ensysce Biosciences?

Summary

How does CERo Therapeutics compare to Vaccinex?

Summary

How does CERo Therapeutics compare to Avalon GloboCare?

Summary

How does CERo Therapeutics compare to CASI Pharmaceuticals?

Summary

How does CERo Therapeutics compare to Sunshine Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO vs. The Competition

CERo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CERo Therapeutics (CERO) Competitors

CERO vs. ENSC, VCNX, ALBT, CASI, and SBFM

How does CERo Therapeutics compare to Ensysce Biosciences?

Do institutionals and insiders have more ownership in ENSC or CERO?

Do analysts rate ENSC or CERO?

Which has better earnings and valuation, ENSC or CERO?

Does the media prefer ENSC or CERO?

Is ENSC or CERO more profitable?

Which has more volatility & risk, ENSC or CERO?

Summary

How does CERo Therapeutics compare to Vaccinex?

Do insiders & institutionals hold more shares of CERO or VCNX?

Does the media favor CERO or VCNX?

Which has stronger earnings and valuation, CERO or VCNX?

Which has more volatility & risk, CERO or VCNX?

Do analysts prefer CERO or VCNX?

Is CERO or VCNX more profitable?

Summary

How does CERo Therapeutics compare to Avalon GloboCare?

Do analysts rate CERO or ALBT?

Does the media refer more to CERO or ALBT?

Which has more volatility & risk, CERO or ALBT?

Do insiders and institutionals hold more shares of CERO or ALBT?

Is CERO or ALBT more profitable?

Which has higher earnings and valuation, CERO or ALBT?

Summary

How does CERo Therapeutics compare to CASI Pharmaceuticals?

Which has more volatility and risk, CASI or CERO?

Do insiders & institutionals have more ownership in CASI or CERO?

Does the media refer more to CASI or CERO?

Which has stronger earnings and valuation, CASI or CERO?

Do analysts recommend CASI or CERO?

Is CASI or CERO more profitable?

Summary

How does CERo Therapeutics compare to Sunshine Biopharma?

Which has more risk and volatility, CERO or SBFM?

Does the media refer more to CERO or SBFM?

Do insiders & institutionals hold more shares of CERO or SBFM?

Which has better earnings and valuation, CERO or SBFM?

Is CERO or SBFM more profitable?

Do analysts recommend CERO or SBFM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO vs. The Competition

CERo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools